Letolizumab (INN; development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

This drug was developed by Bristol-Myers Squibb.

References


Bevacizumab plus Erlotinib ist Therapieoption bei nicht Plattenepithel

Chin J Cancer Res

Atezolizumab translates into survival benefit for bladder cancer

Elotuzumab Improves Upon KRd in Newly Diagnosed Multiple Myeloma

IJMS Free FullText Predicting of Atezolizumab and